New drug trial aims to beat exhaustion from Tick-Borne disease
NCT ID NCT06656351
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This phase 2 study tests the drug tafenoquine in 40 adults with chronic babesiosis who have severe fatigue. The goal is to see if tafenoquine can reduce fatigue and clear the Babesia parasite from the blood. Participants take the drug and report their fatigue levels using a standard questionnaire.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC BABESIOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tafenoquine
What this could lead to
If it works, this could provide a treatment option for chronic babesiosis patients suffering from severe fatigue.
What could go wrong
This is a small, early-phase trial with only 40 participants and no placebo group, so results may not be conclusive. The drug may not improve fatigue or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.